Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran
Received 4 July 2016
Accepted for publication 23 September 2016
Published 7 December 2016 Volume 2016:9 Pages 7385—7395
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Roya Dolatkhah,1 Mohammad Hossein Somi,2 Iraj Asvadi Kermani,1 Morteza Bonyadi,3 Bita Sepehri,2 Kamal Boostani,2 Saleh Azadbakht,2 Nikou Fotouhi,2 Faris Farassati,4 Saeed Dastgiri1,5
1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 2Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; 3Center of Excellence for Biodiversity, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran; 4Molecular Medicine Laboratory, University of Kansas Medical School, Kansas City, KS, USA; 5Tabriz Health Services Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Background: Colorectal cancer (CRC) is the third-most common cancer in Iran. The increasing incidence of CRC in the past three decades has made it a major public health burden in the country. This study aimed to determine any relationship of specific mutations in CRCs with clinicopathologic aspects and outcome of patients.
Materials and methods: This study was conducted on 100 CRC patients by the case-only method. Polymerase chain-reaction products were analyzed by Sanger sequencing, and sequence results were compared with the significant KRAS and BRAF gene mutations in the My Cancer Genome database. Logistic regression models were used to detect associations of clinicopathologic characteristics with each of the mutations. Kaplan–Meier and Cox regression models were constructed to estimate overall survival in patients.
Results: A total of 26 subjects (26%) had heterozygote-mutant KRAS, and mutations were not detected in the amplified exon of BRAF in both tumor and normal tissues of the 100 CRCs. Rectal tumors had 1.53-fold higher likelihood of KRAS mutations than colon tumors, and men had 1.37-fold higher odds than women. The presence of metastasis increased the likelihood of KRAS mutations 2.36-fold over those with nonmetastatic CRCs. Compared to patients with KRAS wild-type cancers, those with KRAS mutations had significantly higher mortality (hazard ratio 3.74, 95% confidence interval 1.44–9.68; log-rank P=0.003).
Conclusion: Better understanding of the causality of CRC can be established by combining epidemiology and research on molecular mechanisms of the disease.
Keywords: proto-oncogene, sequence analysis, regression, colorectal cancer, survival
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]